The Chemours Company (NYSE:CC) Given Average Rating of “Hold” by Brokerages

The Chemours Company (NYSE:CC) has been assigned an average rating of “Hold” from the eight analysts that are currently covering the firm, Marketbeat reports. Five analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $24.88.

Several equities research analysts recently commented on the company. BMO Capital Markets boosted their target price on Chemours from $30.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, October 7th. Royal Bank of Canada reissued an “outperform” rating and issued a $25.00 price objective on shares of Chemours in a research note on Thursday, December 12th. Morgan Stanley decreased their target price on Chemours from $30.00 to $25.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 5th. Finally, Barclays boosted their price target on shares of Chemours from $21.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th.

Chemours Price Performance

Shares of CC opened at $16.69 on Friday. Chemours has a one year low of $15.10 and a one year high of $32.48. The stock’s fifty day moving average is $19.31 and its 200-day moving average is $20.07. The company has a debt-to-equity ratio of 6.05, a quick ratio of 0.92 and a current ratio of 1.73. The firm has a market capitalization of $2.49 billion, a price-to-earnings ratio of 33.38 and a beta of 1.83.

Chemours (NYSE:CC) last released its earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.32 by $0.08. The firm had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.44 billion. Chemours had a net margin of 1.34% and a return on equity of 29.48%. Chemours’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter last year, the company earned $0.64 EPS. Equities analysts anticipate that Chemours will post 1.35 EPS for the current year.

Chemours Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 16th. Shareholders of record on Friday, November 15th were issued a dividend of $0.25 per share. The ex-dividend date of this dividend was Friday, November 15th. This represents a $1.00 annualized dividend and a yield of 5.99%. Chemours’s payout ratio is presently 200.00%.

Insiders Place Their Bets

In other Chemours news, SVP Alvenia Scarborough sold 7,500 shares of the business’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $20.64, for a total transaction of $154,800.00. Following the sale, the senior vice president now directly owns 16,645 shares of the company’s stock, valued at $343,552.80. The trade was a 31.06 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.47% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC boosted its position in Chemours by 3.5% during the 3rd quarter. FMR LLC now owns 18,142,202 shares of the specialty chemicals company’s stock worth $368,650,000 after acquiring an additional 618,361 shares during the period. Marshall Wace LLP lifted its position in shares of Chemours by 23.8% in the second quarter. Marshall Wace LLP now owns 7,009,868 shares of the specialty chemicals company’s stock worth $158,213,000 after purchasing an additional 1,347,710 shares in the last quarter. Khrom Capital Management LLC boosted its holdings in shares of Chemours by 54.6% during the second quarter. Khrom Capital Management LLC now owns 3,456,626 shares of the specialty chemicals company’s stock worth $78,016,000 after purchasing an additional 1,220,967 shares during the period. Geode Capital Management LLC grew its position in Chemours by 1.2% during the third quarter. Geode Capital Management LLC now owns 2,491,748 shares of the specialty chemicals company’s stock valued at $50,646,000 after purchasing an additional 28,803 shares in the last quarter. Finally, American Century Companies Inc. grew its position in Chemours by 26.7% during the second quarter. American Century Companies Inc. now owns 1,811,957 shares of the specialty chemicals company’s stock valued at $40,896,000 after purchasing an additional 382,100 shares in the last quarter. Hedge funds and other institutional investors own 76.26% of the company’s stock.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.